BC
CPRX

Broadfin Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Broadfin Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-880,303
Closed -$4.67M – 43
2019
Q3 		$4.67M Sell
880,303
-1,884,767
-68% -$10M 0.86% 31
2019
Q2 		$10.6M Sell
2,765,070
-3,091,928
-53% -$13.4M 2.31% 15
2019
Q1 		$29.9M Sell
5,856,998
-411,300
-7% -$1.21M 6.17% 3
2018
Q4 		$12M Buy
6,268,298
+1,132,034
+22% +$3.24M 1.58% 18
2018
Q3 		$19.4M Sell
5,136,264
-1,636,500
-24% -$5.13M 2.86% 12
2018
Q2 		$21.1M Sell
6,772,764
-40,000
-0.6% -$121K 3.33% 10
2018
Q1 		$16.3M Sell
6,812,764
-284,536
-4% -$946K 2.54% 15
2017
Q4 		$27.8M Buy
7,097,300
+204,800
+3% +$677K 4.54% 9
2017
Q3 		$17.4M Sell
6,892,500
-457,500
-6% -$1.25M 2.57% 16
2017
Q2 		$20.3M Sell
7,350,000
-850,000
-10% -$1.77M 2.46% 14
2017
Q1 		$16M Hold
8,200,000
– – 1.94% 17
2016
Q4 		$8.61M Hold
8,200,000
– – 0.96% 34
2016
Q3 		$8.94M Hold
8,200,000
– – 0.8% 39
2016
Q2 		$5.82M Hold
8,200,000
– – 0.57% 45
2016
Q1 		$9.59M Buy
8,200,000
+4,016,823
+96% +$6.23M 0.93% 30
2015
Q4 		$10.2M Hold
4,183,177
– – 0.63% 42
2015
Q3 		$12.6M Hold
4,183,177
– – 0.7% 33
2015
Q2 		$17.3M Buy
4,183,177
+100,000
+2% +$399K 0.93% 30
2015
Q1 		$17.7M Buy
4,083,177
+1,683,177
+70% +$6.07M 1.38% 17
2014
Q4 		$7.13M Buy
2,400,000
+1,000,000
+71% +$2.74M 0.62% 42
2014
Q3 		$4.65M Sell
1,400,000
-1,000,000
-42% -$2.61M 0.49% 51
2014
Q2 		$6.07M Buy
+2,400,000
New +$5.13M 0.59% 46

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Broadfin Capital's CPRX Position: Q4 2019 in Review

Broadfin Capital sold out of Catalyst Pharmaceutical (CPRX) in Q4 2019, closing a stake of 880,303 shares — an estimated $4.67M sold.

Broadfin Capital first reported a position in CPRX in Q2 2014 and held it in 22 quarters. The position peaked at $29.9M in Q1 2019. 130 funds tracked by Wall St. Rank hold CPRX as of Q4 2019.

  • Broadfin Capital reported no remaining Catalyst Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • Broadfin Capital sold 880,303 Catalyst Pharmaceutical shares in Q4 2019, an estimated $4.67M.
  • Broadfin Capital first reported a position in Catalyst Pharmaceutical in Q2 2014 and held it in 22 quarters.
  • Broadfin Capital's Catalyst Pharmaceutical position peaked at $29.9M in Q1 2019.
  • 130 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.